129 related articles for article (PubMed ID: 38531054)
1. Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation.
Kesarwani M; Kincaid Z; Azhar M; Azam M
Blood Adv; 2024 Jun; 8(11):2765-2776. PubMed ID: 38531054
[TBL] [Abstract][Full Text] [Related]
2. MAPK-negative feedback regulation confers dependence to JAK2
Kesarwani M; Kincaid Z; Azhar M; Menke J; Schwieterman J; Ansari S; Reaves A; Deininger ME; Levine R; Grimes HL; Azam M
Leukemia; 2023 Aug; 37(8):1686-1697. PubMed ID: 37430058
[TBL] [Abstract][Full Text] [Related]
3. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
[TBL] [Abstract][Full Text] [Related]
4. Enhanced MAPK signaling is essential for CSF3R-induced leukemia.
Rohrabaugh S; Kesarwani M; Kincaid Z; Huber E; Leddonne J; Siddiqui Z; Khalifa Y; Komurov K; Grimes HL; Azam M
Leukemia; 2017 Aug; 31(8):1770-1778. PubMed ID: 28031554
[TBL] [Abstract][Full Text] [Related]
5. A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.
Spiciarich DR; Oh ST; Foley A; Hughes SB; Mauro MJ; Abdel-Wahab O; Press RD; Viner R; Thompson SL; Chen Q; Azadi P; Bertozzi CR; Maxson JE
Cancer Res; 2018 Dec; 78(24):6762-6770. PubMed ID: 30348809
[TBL] [Abstract][Full Text] [Related]
6. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Kesarwani M; Kincaid Z; Gomaa A; Huber E; Rohrabaugh S; Siddiqui Z; Bouso MF; Latif T; Xu M; Komurov K; Mulloy JC; Cancelas JA; Grimes HL; Azam M
Nat Med; 2017 Apr; 23(4):472-482. PubMed ID: 28319094
[TBL] [Abstract][Full Text] [Related]
7. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
[TBL] [Abstract][Full Text] [Related]
8. Roles for the mitogen-activated protein kinase (MAPK) phosphatase, DUSP1, in feedback control of inflammatory gene expression and repression by dexamethasone.
Shah S; King EM; Chandrasekhar A; Newton R
J Biol Chem; 2014 May; 289(19):13667-79. PubMed ID: 24692548
[TBL] [Abstract][Full Text] [Related]
9. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
10. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between the p38alpha and JNK MAPK pathways mediated by MAP kinase phosphatase-1 determines cellular sensitivity to UV radiation.
Staples CJ; Owens DM; Maier JV; Cato AC; Keyse SM
J Biol Chem; 2010 Aug; 285(34):25928-40. PubMed ID: 20547488
[TBL] [Abstract][Full Text] [Related]
12. Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Gil-Araujo B; Toledo Lobo MV; Gutiérrez-Salmerón M; Gutiérrez-Pitalúa J; Ropero S; Angulo JC; Chiloeches A; Lasa M
Mol Oncol; 2014 Feb; 8(1):27-38. PubMed ID: 24080497
[TBL] [Abstract][Full Text] [Related]
13. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Lopes LJS; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia-Filho RJ; Toledo SRC
Mol Carcinog; 2017 Jun; 56(6):1630-1641. PubMed ID: 28112450
[TBL] [Abstract][Full Text] [Related]
14. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.
Maxson JE; Luty SB; MacManiman JD; Abel ML; Druker BJ; Tyner JW
J Biol Chem; 2014 Feb; 289(9):5820-7. PubMed ID: 24403076
[TBL] [Abstract][Full Text] [Related]
15. CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual-specificity phosphatase 1.
Pan J; Lin M; Xu Z; Xu M; Zhang J; Weng Z; Lin B; Lin X
Carcinogenesis; 2021 Nov; 42(11):1399-1409. PubMed ID: 34436551
[TBL] [Abstract][Full Text] [Related]
16. DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.
Kang YS; Seok HJ; Jeong EJ; Kim Y; Yun SJ; Min JK; Kim SJ; Kim JS
Biochem Biophys Res Commun; 2016 Sep; 478(1):403-409. PubMed ID: 27422607
[TBL] [Abstract][Full Text] [Related]
17. Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy.
Shen J; Zhang Y; Yu H; Shen B; Liang Y; Jin R; Liu X; Shi L; Cai X
Cancer Med; 2016 Aug; 5(8):2061-8. PubMed ID: 27227569
[TBL] [Abstract][Full Text] [Related]
18. USP49 inhibits ischemia-reperfusion-induced cell viability suppression and apoptosis in human AC16 cardiomyocytes through DUSP1-JNK1/2 signaling.
Zhang W; Zhang Y; Zhang H; Zhao Q; Liu Z; Xu Y
J Cell Physiol; 2019 May; 234(5):6529-6538. PubMed ID: 30246457
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.
Zhang H; Coblentz C; Watanabe-Smith K; Means S; Means J; Maxson JE; Tyner JW
J Biol Chem; 2018 May; 293(19):7387-7396. PubMed ID: 29572350
[TBL] [Abstract][Full Text] [Related]
20. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
